Biogen (BUE:BIIB) Total Tax Payable

: ARS46,523 Mil (As of Mar. 2023)

View and export this data going back to 2019. Start your Free Trial

Biogen's Total Tax Payable for the quarter that ended in Mar. 2023 was ARS46,523 Mil.

Biogen's quarterly Total Tax Payable increased from Sep. 2022 (ARS32,973 Mil) to Dec. 2022 (ARS43,572 Mil) and increased from Dec. 2022 (ARS43,572 Mil) to Mar. 2023 (ARS46,523 Mil).

Biogen's annual Total Tax Payable increased from Dec. 2020 (ARS11,556 Mil) to Dec. 2021 (ARS17,643 Mil) and increased from Dec. 2021 (ARS17,643 Mil) to Dec. 2022 (ARS43,572 Mil).

Biogen Total Tax Payable Historical Data

The historical data trend for Biogen's Total Tax Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Total Tax Payable

2,394.27

4,267.84

11,555.96

17,642.95

43,572.23

Biogen Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
Total Tax Payable																34,069.15	34,282.02	32,972.84	43,572.23	46,523.03

Biogen Total Tax Payable Calculation

Total Tax Payable is the taxes liability owed to federal, state, and local tax authorities. It is the carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes.

Biogen Total Tax Payable Related Terms

Thank you for viewing the detailed overview of Biogen's Total Tax Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Biogen (BUE:BIIB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biogen Inc (BUE:BIIB) » Definitions » Total Tax Payable

Comparable Companies

Traded in Other Exchanges

BIIB:USA BIIB:Mexico IDP:Germany BIIB34:Brazil BIIB:Austria

Address

225 Binney Street, Cambridge, MA, USA, 02142

Website

http://www.biogen.com

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021, followed by Leqembi in January 2023.